Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Clancy

Showing results (211-220 of 226) with videos related to

Pageof 23
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
American Journal of Respiratory and Critical Care Medicine|January 15, 2019
Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research StatementAnn Chen Wu, James P Kiley, Patricia J Noel, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Phenotypic plasticity evolved for climate variability constrains performance under climate warmingAlayna Mead, Michelle Zavala-Paez, Joie R Beasley-Bennett, et al.
Frontiers in Immunology|January 27, 2023
Alpha-1 antitrypsin limits neutrophil extracellular trap disruption of airway epithelial barrier functionK M Hudock, M S Collins, M A Imbrogno, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
JAMA Pediatrics|May 5, 2015
Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trialScott W Powers, Lori J Stark, Leigh A Chamberlin, et al.
Cell Host & Microbe|August 6, 2025
Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammationSamantha L Durfey, Siddhartha G Kapnadak, Tahuanty Pena, et al.
JCI Insight|April 19, 2019
A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucusCourtney M Fernandez-Petty, Gareth W Hughes, Hannah L Bowers, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator eraN Mayer-Hamblett, S van Koningsbruggen-Rietschel, D P Nichols, et al.
Nature Biotechnology|June 10, 2014
The Synthetic Biology Open Language (SBOL) provides a community standard for communicating designs in synthetic biologyMichal Galdzicki, Kevin P Clancy, Ernst Oberortner, et al.
Pageof 23

Showing results (211-220 of 226) with videos related to

Sort By:
Pageof 23
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 24, 2022
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GISarah Jane Schwarzenberg, Phuong T Vu, Michelle Skalland, et al.
American Journal of Respiratory and Critical Care Medicine|January 15, 2019
Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research StatementAnn Chen Wu, James P Kiley, Patricia J Noel, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Phenotypic plasticity evolved for climate variability constrains performance under climate warmingAlayna Mead, Michelle Zavala-Paez, Joie R Beasley-Bennett, et al.
Frontiers in Immunology|January 27, 2023
Alpha-1 antitrypsin limits neutrophil extracellular trap disruption of airway epithelial barrier functionK M Hudock, M S Collins, M A Imbrogno, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2021
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical TrialDavid P Nichols, Alex C Paynter, Sonya L Heltshe, et al.
JAMA Pediatrics|May 5, 2015
Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trialScott W Powers, Lori J Stark, Leigh A Chamberlin, et al.
Cell Host & Microbe|August 6, 2025
Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammationSamantha L Durfey, Siddhartha G Kapnadak, Tahuanty Pena, et al.
JCI Insight|April 19, 2019
A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucusCourtney M Fernandez-Petty, Gareth W Hughes, Hannah L Bowers, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2020
Building global development strategies for cf therapeutics during a transitional cftr modulator eraN Mayer-Hamblett, S van Koningsbruggen-Rietschel, D P Nichols, et al.
Nature Biotechnology|June 10, 2014
The Synthetic Biology Open Language (SBOL) provides a community standard for communicating designs in synthetic biologyMichal Galdzicki, Kevin P Clancy, Ernst Oberortner, et al.
Pageof 23